DexCom, Inc. (NASDAQ:DXCM) SVP Matthew Vincent Dolan Sells 2,303 Shares

DexCom, Inc. (NASDAQ:DXCM – Get Rating) SVP Matthew Vincent Dolan sold 2,303 shares of the firm’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $115.00, for a total value of $264,845.00. Following the transaction, the senior vice president now directly owns 33,569 shares in the company, valued at approximately $3,860,435. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Matthew Vincent Dolan also recently made the following trade(s):

• On Monday, March 13th, Matthew Vincent Dolan sold 6,229 shares of DexCom stock. The stock was sold at an average price of $106.27, for a total value of $661,955.83.
• On Monday, March 6th, Matthew Vincent Dolan sold 226 shares of DexCom stock. The stock was sold at an average price of $114.40, for a total value of $25,854.40.

DexCom Price Performance

Shares of DXCM stock traded down $0.63 during midday trading on Friday, reaching $113.93. 2,623,893 shares of the company traded hands, compared to its average volume of 2,657,800. The firm’s 50 day simple moving average is $111.05 and its two-hundred day simple moving average is $106.34. DexCom, Inc. has a 1-year low of $66.89 and a 1-year high of $134.76. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.99 and a quick ratio of 1.83. The firm has a market cap of $44.02 billion, a PE ratio of 140.22, a price-to-earnings-growth ratio of 2.75 and a beta of 1.10.

DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings results on Thursday, February 9th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. DexCom had a net margin of 11.73% and a return on equity of 16.66%. The company had revenue of $815.20 million during the quarter, compared to the consensus estimate of $814.52 million. During the same period last year, the firm earned $0.17 EPS. The company’s revenue for the quarter was up 16.8% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 1.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DXCM shares. Citigroup increased their target price on shares of DexCom from $117.00 to $146.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Stifel Nicolaus increased their target price on shares of DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. Cowen increased their target price on shares of DexCom from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Friday, February 10th. StockNews.com started coverage on shares of DexCom in a research note on Thursday. They set a “hold” rating for the company. Finally, Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the stock an “equal weight” rating in a research note on Friday, January 6th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $123.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC increased its stake in shares of DexCom by 300.0% during the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock worth $26,000 after purchasing an additional 240 shares in the last quarter. Ronald Blue Trust Inc. increased its stake in shares of DexCom by 860.5% during the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock worth $27,000 after purchasing an additional 327 shares in the last quarter. James Investment Research Inc. purchased a new position in shares of DexCom during the 4th quarter worth approximately $27,000. Private Trust Co. NA purchased a new position in shares of DexCom during the 2nd quarter worth approximately $29,000. Finally, Close Asset Management Ltd grew its stake in DexCom by 200.0% in the 4th quarter. Close Asset Management Ltd now owns 264 shares of the medical device company’s stock worth $30,000 after acquiring an additional 176 shares during the period. 94.01% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.